Fernández Martínez Paula, Aguado García Rocío, Barajas Galindo David Emilio, Hernández Moreno Ana, Alejo Ramos Mirian, García Arias Sara, Ballesteros Pomar María D, Cano Rodríguez Isidoro Manuel
Sección de Endocrinología y Nutrición, Complejo Asistencial Universitario de León, León, Spain.
Sección de Endocrinología y Nutrición, Complejo Asistencial Universitario de León, León, Spain.
Endocrinol Diabetes Nutr (Engl Ed). 2018 Oct;65(8):444-450. doi: 10.1016/j.endinu.2018.05.004. Epub 2018 Jun 14.
During pregnancy, thyroid peroxidase (TPO) antibodies may increase the risk of developing subclinical hypothyroidism (SCH). Both conditions appear to be associated to maternal-fetal complications. The objectives of this study were to analyze if a relationship exists between TSH and TPO levels during pregnancy and the potential effects on gestational and perinatal complications, and to assess whether detectable, but not positive, TPO levels have an impact on development of gestational SCH.
A prospective study was conducted at the Leon Health Area (CAULE), where universal screening for gestational thyroid dysfunction is performed between weeks 7-13 of pregnancy. Data on TSH and TPO levels and gestational and perinatal complications were collected for all 2016 deliveries. Positive TPO antibodies were defined as values≥35IU/mL. In a previous study, a TSH level>3.72mU/L was established as the cut-off value for gestational SCH.
Records corresponding to 1,980 deliveries at CAULE, 21 abortions, and 18 deliveries outside the hospital were analyzed. Of the 1,670 pregnant women screened (84.34%), 142 (8.50%) had positive TPO antibodies and their presence was associated to diagnosis of SCH (P<0.01) and to significantly higher mean TSH levels (3.51mU/L vs. 2.46mU/L, P=0.03). There were no significant differences in gestational or neonatal complications. In the group with undetectable TPO antibodies (<10lU/mL), the mean TSH levels was slightly lower than in the group with TPO values ranging from 10-35 IU/mL, but the difference was not significant (P=0.89).
Presence of positive TPO antibodies is associated to higher TSH levels and higher risk of gestational SCH, but does not increase the rate of maternal-fetal complications.
在孕期,甲状腺过氧化物酶(TPO)抗体可能会增加亚临床甲状腺功能减退症(SCH)的发病风险。这两种情况似乎都与母胎并发症有关。本研究的目的是分析孕期促甲状腺激素(TSH)和TPO水平之间是否存在关联以及对妊娠和围产期并发症的潜在影响,并评估可检测到但为阴性的TPO水平是否会对妊娠期SCH的发生产生影响。
在莱昂健康区(CAULE)进行了一项前瞻性研究,在妊娠7至13周期间对妊娠甲状腺功能障碍进行普遍筛查。收集了2016年所有分娩的TSH和TPO水平以及妊娠和围产期并发症的数据。TPO抗体阳性定义为值≥35IU/mL。在先前的一项研究中,将TSH水平>3.72mU/L确定为妊娠期SCH的临界值。
分析了CAULE的1980例分娩记录、21例流产记录和18例院外分娩记录。在1670名接受筛查的孕妇中(84.34%),142名(8.50%)TPO抗体呈阳性,其存在与SCH诊断相关(P<0.01),且平均TSH水平显著更高(3.51mU/L对2.46mU/L,P=0.03)。妊娠或新生儿并发症方面无显著差异。在TPO抗体检测不到(<10lU/mL)的组中,平均TSH水平略低于TPO值在10 - 35IU/mL之间的组,但差异不显著(P=0.89)。
TPO抗体阳性与较高的TSH水平及妊娠期SCH的较高风险相关,但不会增加母胎并发症的发生率。